

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
PANC-F (3 of 12, 4 of 12, 5 of 12, and 6 of 12) External request: Submission from Ipsen Biopharmaceuticals (01/20/2023) to consider the inclusion of NALIRIFOX: - PANC-F (3 of 12): Add liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a preferred regimen for first-line therapy in patients with locally advanced pancreatic adenocarcinoma. Include a footnote that NALIRIFOX is reasonable in patients with ECOG of 0–2. - PANC-F (5 of 12): Add liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a preferred regimen for first-line therapy in patients with metastatic pancreatic adenocarcinoma disease. Include a footnote that NALIRIFOX is reasonable in patients with ECOG of 0–2.	Based on the review of the data in the noted references, the panel consensus was to include NALIRIFOX as: - PANC-F (3 of 12): First-line therapy option for patients with locally advanced pancreatic adenocarcinoma and Good PS 0-1. This is a category 2A, Other Recommended regimen. Footnote i added: While NCCN recognizes that there is high-level evidence supporting the use of NALIRIFOX over gemcitabine and albumin-bound paclitaxel, it should be recognized that this regimen does not appear to have an advantage over FOLFIRINOX and adds considerably more expense compared to FOLFIRINOX. - PANC-F (4 of 12): First-line therapy option for patients with locally advanced pancreatic adenocarcinoma and Intermediate PS 2. This is a category 2B, Useful in Certain Circumstances recommendation. Footnote i added: While NCCN recognizes that there is high-level evidence supporting the use of NALIRIFOX over gemcitabine and albumin-bound paclitaxel, it should be recognized that this regimen does not appear to have an advantage over FOLFIRINOX and adds considerably more expense compared to FOLFIRINOX. - PANC-F (5 of 12): First-line therapy option for patients with metastatic pancreatic adenocarcinoma and Good PS 0-1. This is a category 2A, Other Recommended regimen. Footnote i added: While NCCN recognizes that there is high-level evidence supporting the use of NALIRIFOX over gemcitabine and albumin-bound paclitaxel, it should be	19	3	5	6
		11	11	5	6
		21	1	5	6

	recognized that this regimen does not appear to have an advantage over FOLFIRINOX and adds considerably more expense compared to FOLFIRINOX. • PANC-F (6 of 12): First-line therapy option for patients with metastatic pancreatic adenocarcinoma and Intermediate PS 2. This is a category 2B, Useful in Certain Circumstances recommendation. Footnote i added: While NCCN recognizes that there is high-level evidence supporting the use of NALIRIFOX over gemcitabine and albumin-bound paclitaxel, it should be recognized that this regimen does not appear to have an advantage over FOLFIRINOX and adds considerably more expense compared to FOLFIRINOX.	12	10	5	6
--	---	----	----	---	---